Retinal vein occlusion (RVO) is a serious eye condition, but how much it threatens your vision depends heavily on which type you have and how quickly it’s treated. In the milder form, branch retinal vein occlusion, 50 to 60% of eyes retain good vision (20/40 or better) even without treatment. In the more severe form, central retinal vein occlusion, the risks of significant vision loss and dangerous complications climb substantially. Either way, RVO also signals underlying cardiovascular problems that deserve attention beyond your eyes.
Branch vs. Central: Two Different Levels of Risk
RVO comes in two main types based on where the blockage happens. Branch retinal vein occlusion (BRVO) blocks one of the smaller veins branching off the main retinal vein, affecting only a portion of the retina. Central retinal vein occlusion (CRVO) blocks the main vein itself, disrupting blood flow across the entire retina. BRVO is four to six times more common than CRVO.
The distinction matters because CRVO carries significantly worse visual outcomes and a higher risk of complications. With BRVO, your starting vision is a strong predictor of where you’ll end up. If your vision is relatively preserved at the time of diagnosis (20/50 or better), only about 0 to 5% of eyes deteriorate to severe vision loss. But if your initial vision is already poor (20/200 or worse), 50 to 83% of eyes remain in that range long term.
CRVO is also subdivided into ischemic and non-ischemic types. The ischemic form, where large areas of the retina lose their blood supply, is the most dangerous. Up to 60% of people with ischemic CRVO develop abnormal new blood vessel growth in the front of the eye within weeks to two years, which can lead to a particularly aggressive form of glaucoma.
What It Feels Like When It Happens
RVO typically strikes one eye, and the hallmark symptom is blurry vision that comes on suddenly or worsens over hours to days. In mild cases of CRVO, you may not notice any symptoms at all. More severe cases can bring noticeable vision loss, and some people experience eye pain or redness. There’s no pain in most cases, which is part of what makes it easy to dismiss early on.
Unlike a retinal artery occlusion (a related but different emergency), RVO doesn’t always present as a dramatic, seconds-long blackout. The blurriness can develop gradually enough that some people wait days before seeking care. That delay matters, because the longer the retina stays swollen or oxygen-deprived, the more likely the damage becomes permanent. When oxygen deprivation persists, the delicate structures in the central retina undergo irreversible changes, and the resulting vision loss is almost always lasting.
The Complication That Causes Most Vision Loss
The blockage itself isn’t usually what steals your sight. The main threat is macular edema, a buildup of fluid in the central part of the retina responsible for sharp, detailed vision. When a vein is blocked, pressure backs up in the smaller vessels, and fluid leaks into the surrounding tissue. This swelling distorts and blurs central vision, and without treatment it can cause lasting structural damage to the retina.
A second major complication is neovascular glaucoma, sometimes called “90-day glaucoma” because it classically appears about three months after a CRVO. In reality, it can show up anywhere from two weeks to two years later, though over 80% of cases develop within six months. This happens when oxygen-starved retinal tissue triggers the growth of fragile, abnormal blood vessels in the front of the eye. These vessels block the eye’s natural drainage system, causing dangerously high eye pressure that can permanently damage the optic nerve. Between 18 and 60% of people with ischemic CRVO eventually develop this complication.
How Doctors Assess the Damage
Your eye doctor will use imaging to determine how much of the retina is affected and whether areas have lost their blood supply entirely. Two tools are central to this process.
Optical coherence tomography (OCT) creates cross-sectional images of the retina, revealing fluid buildup, swelling, and structural damage at a microscopic level. A newer version called OCT angiography can map the retinal blood vessels without injecting any dye, showing areas where blood flow has dropped off. These non-perfusion areas, as they’re called, are the strongest predictor of how well your vision will hold up. The size of these dead zones correlates directly with visual acuity and retinal sensitivity.
Fluorescein angiography involves injecting a fluorescent dye into a vein in your arm and photographing it as it flows through the retinal vessels. This remains the standard method for identifying ischemic areas across both the central and peripheral retina, and it’s the basis for many treatment decisions. In some cases, OCT angiography findings can help determine whether the more invasive dye test is even necessary. Research suggests that if the small vessels around the fovea (the very center of the retina) appear intact on OCT angiography, peripheral ischemia on the dye test is unlikely.
Treatment Options and What to Expect
The primary treatment for vision-threatening macular edema from RVO is a series of injections into the eye. These injections contain medications that block a protein called VEGF, which drives both fluid leakage and abnormal blood vessel growth. Across clinical trials, patients receiving these injections gained an average of about 15 letters on a standard eye chart, roughly equivalent to reading three additional lines. That’s a meaningful improvement for most people, often the difference between struggling to read and reading comfortably.
The catch is that these injections aren’t one-and-done. Most people need repeated treatments over months or years, with the frequency tapering as the condition stabilizes. The injections themselves are quick (the actual injection takes seconds), done under numbing drops, and while the idea sounds alarming, most patients describe the experience as uncomfortable rather than painful.
Laser treatment still plays a role in certain situations. Grid laser photocoagulation is used for chronic swelling in BRVO and has a strong safety record, with lower risks of elevated eye pressure and cataracts compared to steroid injections. Scatter laser treatment is reserved for cases where dangerous new blood vessels have started growing, particularly in ischemic CRVO where neovascular glaucoma is a threat. In some cases, laser and injection therapy are combined.
What RVO Reveals About Your Overall Health
RVO is not just an eye problem. It’s a vascular event, and the conditions that cause it are the same ones that drive heart disease and stroke. The risk factor profiles differ somewhat between the two types. BRVO is more strongly associated with high blood pressure, peripheral vascular disease, and atherosclerosis (hardening of the arteries). People with BRVO tend to have higher diastolic blood pressure, by about 7 mmHg on average, compared to those with CRVO.
CRVO, on the other hand, shows stronger links to diabetes, chronic kidney disease, and elevated homocysteine levels (an amino acid tied to blood vessel damage). In one large study, 23.5% of CRVO patients had abnormally high homocysteine levels compared to just 8.4% of BRVO patients. CRVO patients also showed higher blood sugar, lower hemoglobin, and elevated markers of kidney dysfunction.
There’s also crossover risk. About 6% of people first diagnosed with CRVO went on to develop BRVO during follow-up, and roughly 1% of BRVO patients later developed CRVO. That crossover rate was significantly higher in the CRVO group, suggesting more widespread vascular vulnerability.
If you’ve been diagnosed with RVO, your eye doctor will likely recommend a full cardiovascular workup, including blood pressure monitoring, blood sugar testing, kidney function tests, and cholesterol screening. Managing these underlying conditions isn’t just about protecting your other eye. It’s about reducing your risk of heart attack and stroke, which share the same root causes as the blockage in your retina.